当前位置: X-MOL 学术J. Drug Target. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
New advances in brain-targeting nano-drug delivery systems for Alzheimer's disease
Journal of Drug Targeting ( IF 4.5 ) Pub Date : 2021-05-20 , DOI: 10.1080/1061186x.2021.1927055
Qin Ouyang 1 , Yingcai Meng 1 , Wenhu Zhou 1 , Jianbin Tong 2, 3 , Zeneng Cheng 1 , Qubo Zhu 1
Affiliation  

Abstract

Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide and its incidence is increasing due to the ageing population. Currently, the main limitations of AD treatment are low blood–brain barrier permeability, severe off-target of drugs, and immune abnormality. In this review, four hypotheses for Alzheimer's pathogenesis and three challenges for Alzheimer's drug delivery are discussed. In addition, this article summarises the different strategies of brain targeting nano-drug delivery systems (NDDSs) developed in the last 10 years. These strategies include receptor-mediated (transferrin receptor, low-density lipoprotein receptor-related protein, lactoferrin receptor, etc.), adsorption-mediated (cationic, alkaline polypeptide, cell-penetrating peptides, etc.), and transporter-mediated (P-gp, GLUT1, etc.). Moreover, it provides insights into novel strategies used in AD, such as exosomes, virus-like particles, and cell membrane coating particles. Hence, this review will help researchers to understand the current progress in the field of NDDSs for the central nervous system and find new directions for AD therapy.

  • Highlights
  • Characteristics and challenges based on the pathogenesis of AD were discussed.

  • Recent advances in novel brain-targeting NDDSs for AD over the past 10 years were summarised.



中文翻译:

用于治疗阿尔茨海默病的脑靶向纳米药物递送系统的新进展

摘要

阿尔茨海默病 (AD) 是全球最常见的神经退行性疾病,随着人口老龄化,其发病率正在增加。目前,AD治疗的主要局限是血脑屏障通透性低、药物脱靶严重和免疫异常。在这篇综述中,讨论了阿尔茨海默病发病机制的四个假设和阿尔茨海默病药物递送的三个挑战。此外,本文总结了过去 10 年开发的脑靶向纳米药物递送系统 (NDDS) 的不同策略。这些策略包括受体介导的(转铁蛋白受体、低密度脂蛋白受体相关蛋白、乳铁蛋白受体等)、吸附介导的(阳离子、碱性多肽、细胞穿透肽等)和转运蛋白介导的(P -gp、GLUT1 等)。而且,它提供了对 AD 中使用的新策略的见解,例如外泌体、病毒样颗粒和细胞膜涂层颗粒。因此,本综述将有助于研究人员了解中枢神经系统NDDS领域的当前进展,并为AD治疗找到新的方向。

  • 强调
  • 讨论了基于 AD 发病机制的特征和挑战。

  • 总结了过去 10 年中针对 AD 的新型脑靶向 N​​DDS 的最新进展。

更新日期:2021-05-20
down
wechat
bug